{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T18:21:01Z","timestamp":1792693261282,"version":"4.5.0"},"reference-count":25,"publisher":"Oxford University Press (OUP)","issue":"1","license":[{"start":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T00:00:00Z","timestamp":1772236800000},"content-version":"vor","delay-in-days":58,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,1,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Idiopathic multicentric Castleman\u2019s disease (iMCD) is a systemic lymphoproliferative disorder characterised by interleukin (IL)-6 overproduction. To date, several cases of iMCD with autoimmune features have been reported, and cases of iMCD complicated by IgA vasculitis have also been reported. IL-6 is reported to promote the production of galactose-deficient IgA1, a key pathogenic factor in IgA vasculitis. Therefore, IL-6 overproduction in iMCD may contribute to the development of IgA vasculitis in these cases. Here, we present two cases of iMCD complicated by IgA vasculitis, both successfully treated with tocilizumab, an IL-6 receptor blockade. Furthermore, our literature review identified two reported cases of iMCD complicated by IgA nephropathy, and one case of iMCD complicated by IgA vasculitis, all of which responded favourably to tocilizumab. Our cases and literature review suggest the pathogenic role of IL-6 in the development of IgA vasculitis in iMCD and the effectiveness of tocilizumab as a potential therapeutic option not only for iMCD itself, but also for IgA vasculitis in the setting of iMCD.<\/jats:p>","DOI":"10.1093\/mrcr\/rxag014","type":"journal-article","created":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T12:43:28Z","timestamp":1772196208000},"source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness of tocilizumab for IgA vasculitis associated with idiopathic multicentric Castleman\u2019s disease: Two cases and literature review"],"prefix":"10.1093","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1358-7069","authenticated-orcid":false,"given":"Koji","family":"Suzuki","sequence":"first","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0009-4061-721X","authenticated-orcid":false,"given":"Koichi","family":"Saito","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5075-8977","authenticated-orcid":false,"given":"Mitsuhiro","family":"Akiyama","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akari","family":"Miwa","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo ,","place":["Japan"]},{"name":"Department of General Internal Medicine and Rheumatology, Gifu Municipal Hospital , Gifu ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-0001-1078","authenticated-orcid":false,"given":"Kanako","family":"Shimanuki","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuoto","family":"Hiramoto","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3231-8841","authenticated-orcid":false,"given":"Jun","family":"Kikuchi","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2646-5765","authenticated-orcid":false,"given":"Yuko","family":"Kaneko","sequence":"additional","affiliation":[{"name":"Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine , Tokyo ,","place":["Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,2,28]]},"reference":[{"key":"2026081301163241400_ref1","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1002\/art.43269","article-title":"Expert perspective: diagnosis and treatment of Castleman disease","volume":"78","author":"Chen","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"2026081301163241400_ref2","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1093\/rheumatology\/keab634","article-title":"Immunoglobulin G4-related disease and idiopathic multicentric Castleman\u2019s disease: confusable immune-mediated disorders","volume":"61","author":"Sasaki","year":"2022","journal-title":"Rheumatology (Oxford)"},{"key":"2026081301163241400_ref3","doi-asserted-by":"crossref","DOI":"10.1080\/25785826.2025.2547444","article-title":"Successful tocilizumab monotherapy for multicentric Castleman disease complicated by rheumatoid arthritis and Sj\u00f6gren\u2019s disease: a case-based literature review","author":"Suzuki","year":"2026","journal-title":"Immunol Med"},{"key":"2026081301163241400_ref4","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s00296-025-05880-w","article-title":"Efficacy of tocilizumab monotherapy for autoimmune hemolytic anemia associated with idiopathic multicentric Castleman disease: a case-based review","volume":"45","author":"Suzuki","year":"2025","journal-title":"Rheumatol Int"},{"key":"2026081301163241400_ref5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.cytogfr.2022.04.001","article-title":"IL-6 and its role in IgA nephropathy development","volume":"66","author":"Groza","year":"2022","journal-title":"Cytokine Growth Factor Rev"},{"key":"2026081301163241400_ref6","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1038\/ki.2011.16","article-title":"Aberrant glycosylation of IgA1 is inherited in both pediatric IgA nephropathy and Henoch\u2013Sch\u00f6nlein purpura nephritis","volume":"80","author":"Kiryluk","year":"2011","journal-title":"Kidney Int"},{"key":"2026081301163241400_ref7","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1182\/blood-2016-10-746933","article-title":"International, evidence-based consensus diagnostic criteria for HHV-8-negative\/idiopathic multicentric Castleman disease","volume":"129","author":"Fajgenbaum","year":"2017","journal-title":"Blood."},{"key":"2026081301163241400_ref8","first-page":"798","article-title":"EULAR\/PRINTO\/PRES criteria for Henoch-Sch\u00f6nlein purpura, childhood polyarteritis nodosa, childhood Wegener granulomatosis and childhood Takayasu arteritis: Ankara. Part II: Final classification criteria","volume":"2010","author":"Ozen","year":"2008","journal-title":"Ann Rheum Dis"},{"key":"2026081301163241400_ref9","doi-asserted-by":"crossref","first-page":"e225","DOI":"10.3346\/jkms.2024.39.e225","article-title":"CAse-BAsed REview sTandards (CABARET): considerations for authors, reviewers, and editors","volume":"39","author":"Benlidayi","year":"2024","journal-title":"J Korean Med Sci"},{"key":"2026081301163241400_ref10","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1097\/MAJ.0b013e3181da4321","article-title":"IgA nephropathy associated with Castleman disease with cutaneous involvement","volume":"339","author":"Komatsuda","year":"2010","journal-title":"Am J Med Sci"},{"key":"2026081301163241400_ref11","doi-asserted-by":"crossref","first-page":"677","DOI":"10.1186\/s12882-025-04639-6","article-title":"Use of tocilizumab to treat IgA nephropathy complicated by idiopathic multicentric Castleman disease: a case report","volume":"26","author":"Komeno","year":"2025","journal-title":"BMC Nephrol"},{"key":"2026081301163241400_ref12","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1007\/s10067-017-3568-y","article-title":"Multicentric Castleman\u2019s disease associated with IgA vasculitis (Henoch-Sch\u00f6nlein purpura) responding well to tocilizumab: a case report","volume":"36","author":"Oshima","year":"2017","journal-title":"Clin Rheumatol"},{"key":"2026081301163241400_ref13","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.kint.2017.10.019","article-title":"IgA nephropathy and IgA vasculitis with nephritis have a shared feature involving galactose-deficient IgA1-oriented pathogenesis","volume":"93","author":"Suzuki","year":"2018","journal-title":"Kidney Int"},{"key":"2026081301163241400_ref14","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.3390\/jcm10194501","article-title":"Pathogenesis of IgA nephropathy: current understanding and implications for development of disease-specific treatment","volume":"10","author":"Knoppova","year":"2021","journal-title":"J Clin Med"},{"key":"2026081301163241400_ref15","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.3390\/jcm10112310","article-title":"IgA vasculitis and IgA nephropathy: same disease?","volume":"10","author":"Pillebout","year":"2021","journal-title":"J Clin Med"},{"key":"2026081301163241400_ref16","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s11255-021-03063-7","article-title":"Comparison of clinical, pathological and long-term renal outcomes of children with Henoch-Schonlein purpura nephritis and IgA nephropathy","volume":"54","author":"Torun Bayram","year":"2022","journal-title":"Int Urol Nephrol"},{"key":"2026081301163241400_ref17","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1007\/s10067-014-2773-1","article-title":"Evaluation of serum procalcitonin and C-reactive protein levels as biomarkers of Henoch-Sch\u00f6nlein purpura in pediatric patients","volume":"35","author":"Teng","year":"2016","journal-title":"Clin Rheumatol"},{"key":"2026081301163241400_ref18","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ekir.2022.12.023","article-title":"Elevated urinary IL-6 predicts the progression of IgA nephropathy","volume":"8","author":"Zhao","year":"2023","journal-title":"Kidney Int Rep"},{"key":"2026081301163241400_ref19","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1186\/s12887-019-1802-2","article-title":"Changes of inflammatory mediators and oxidative stress indicators in children with Henoch-Sch\u00f6nlein purpura and clinical effects of hemoperfusion in the treatment of severe Henoch-Sch\u00f6nlein purpura with gastrointestinal involvement in children","volume":"19","author":"Zhu","year":"2019","journal-title":"BMC Pediatr"},{"key":"2026081301163241400_ref20","doi-asserted-by":"crossref","first-page":"e0232194","DOI":"10.1371\/journal.pone.0232194","article-title":"A cross-sectional analysis of clinicopathologic similarities and differences between Henoch-Sch\u00f6nlein purpura nephritis and IgA nephropathy","volume":"15","author":"Sugiyama","year":"2020","journal-title":"PLoS One"},{"key":"2026081301163241400_ref21","doi-asserted-by":"crossref","first-page":"771619","DOI":"10.3389\/fimmu.2021.771619","article-title":"Pathogenesis of IgA vasculitis: an up-to-date review","volume":"12","author":"Song","year":"2021","journal-title":"Front Immunol"},{"key":"2026081301163241400_ref22","doi-asserted-by":"crossref","first-page":"108347","DOI":"10.1016\/j.clim.2020.108347","article-title":"Case report on mesangial proliferative glomerulonephritis with multicentric Castleman\u2019s disease: approach to the onset mechanism of immunoglobulin a nephropathy","volume":"212","author":"Karasawa","year":"2020","journal-title":"Clin Immunol"},{"key":"2026081301163241400_ref23","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1080\/14397595.2018.1532383","article-title":"A benefit and the prospects of IL-6 inhibitors in idiopathic multicentric Castleman\u2019s disease","volume":"29","author":"Koga","year":"2019","journal-title":"Mod Rheumatol"},{"key":"2026081301163241400_ref24","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1182\/blood-2018-07-862334","article-title":"International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease","volume":"132","author":"Rhee","year":"2018","journal-title":"Blood."},{"key":"2026081301163241400_ref25","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1007\/s00277-017-3111-x","article-title":"Interleukin-6 in idiopathic multicentric Castleman\u2019s disease after long-term tocilizumab","volume":"96","author":"Akiyama","year":"2017","journal-title":"Ann Hematol"}],"container-title":["Modern Rheumatology Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/mrcr\/advance-article-pdf\/doi\/10.1093\/mrcr\/rxag014\/67171524\/rxag014.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/10\/1\/rxag014\/67171524\/rxag014.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/mrcr\/article-pdf\/10\/1\/rxag014\/67171524\/rxag014.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,13]],"date-time":"2026-08-13T05:16:43Z","timestamp":1786598203000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/mrcr\/article\/doi\/10.1093\/mrcr\/rxag014\/8502063"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1,6]]}},"URL":"https:\/\/doi.org\/10.1093\/mrcr\/rxag014","relation":{},"ISSN":["2472-5625"],"issn-type":[{"value":"2472-5625","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026]]},"published":{"date-parts":[[2026]]},"article-number":"rxag014"}}